Amgen Drug Combo Reduces Mortality Risk in Aggressive Lung Cancer Patients

OPA WIRE, Oct 24 (OPA) — Amgen announced clinical trial results showing that its drug, when combined with AstraZeneca’s immunotherapy, significantly improved survival rates for patients diagnosed with aggressive lung cancer. The combination therapy demonstrated a 58% reduction in the risk of death compared to standard treatment protocols.

The findings were presented following a rigorous evaluation of patient outcomes during the study. Researchers noted that the synergy between the two medications targeted specific cellular pathways, effectively slowing disease progression in the trial cohort.

Lung cancer remains a leading cause of cancer-related mortality globally, with aggressive variants often proving resistant to conventional chemotherapy. AstraZeneca’s immunotherapy, already a standard in oncology, serves as the backbone for this new combination approach.

Amgen plans to submit these findings to regulatory bodies for potential approval. If cleared, the treatment could reach clinical settings by next year, providing a new standard of care for patients battling advanced-stage disease.